|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
Multiple Sclerosis Information
Favorite Links
This Month
Month Archive
|
Thursday, July 16
by
All About MS
on Thu 16 Jul 2009 11:28 AM CST
Prednisone or acetaminophen may significantly control flulike symptoms (FLSs) in patients with relapsing multiple sclerosis (MS) who are treated with interferon (IFN) beta-1a, according to a study presented here at the more »
Tuesday, March 31
by
All About MS
on Tue 31 Mar 2009 08:14 AM CST
Bayer will launch a titration pack for patients with multiple sclerosis (MS) that is specially designed to make it easier for them to start Betaferon® / Betaseron (interferon beta-1b) therapy. From now on, the titration pack will be available in more »
Thursday, November 6
by
All About MS
on Thu 06 Nov 2008 10:16 AM CST
In this phase 2, randomized, blinded trial involving previously untreated, early, relapsing-remitting multiple sclerosis, we assigned 334 patients with scores of 3.0 or less on the Expanded Disability Status Scale and a disease duration of 3 years or less to receive more »
Tuesday, October 28
by
All About MS
on Tue 28 Oct 2008 08:31 PM CST
Bayer HealthCare Pharmaceuticals Inc. is proud to announce that BETASERON (interferon beta-1b) is now available with a new 30-gauge needle, which is the thinnest needle in MS therapy. The new more »
Friday, April 11
by
All About MS
on Fri 11 Apr 2008 12:00 AM CST
Interferon beta-1b belongs to a class of medications known as immunomodulators. It is used to reduce the frequency of exacerbations (worsening of symptoms) in people suffering with relapsing-remitting multiple sclerosis.
Multiple sclerosis (MS) is caused by more »
Wednesday, March 19
by
All About MS
on Wed 19 Mar 2008 02:00 AM CST
We describe a 41-year-old woman with multiple sclerosis, who presented with redness of the skin; several discoloured areas; along with inflammatory small, more »
Tuesday, February 26
by
All About MS
on Tue 26 Feb 2008 12:00 AM CST
Prolonged therapy with interferon beta (IFNbeta) often leads to the development of anti-IFNbeta binding antibodies (BAbs). A subset of the BAbs is of a neutralizing nature (neutralizing antibodies, NAbs) and more »
Wednesday, February 6
by
All About MS
on Wed 06 Feb 2008 06:57 AM CST
Biogen Idec Inc. and PDL BioPharma, Inc. (PDL) announced
that Phase 2 data demonstrated a significant reduction in new or enlarged gadolinium- enhancing lesions when daclizumab more »
Tuesday, February 5
by
All About MS
on Tue 05 Feb 2008 08:15 AM CST
The glycoprotein integrin is expressed on the surface of these cells and plays a critical part in their adhesion to the vascular endothelium and migration into the parenchyma. Tysabri (Natalizumab) is an integrin antagonist that reduced the development of brain lesions in more »
Monday, February 4
by
All About MS
on Mon 04 Feb 2008 07:20 AM CST
The two-year study showed that treatment with Betaseron delayed the time to a second clinical event by one year compared to placebo. (1) BENEFIT is the only trial to demonstrate the more »
Monday, December 31
by
All About MS
on Mon 31 Dec 2007 09:07 AM CST
BENEFIT Study Shows Interferon Beta-1b Delays Development of MS in Patients with First Clinical Signs of Disease BASEL, SWITZERLAND -- October 14, 2005 – Interferon beta-1b 250 mcg* ... more » Thursday, December 13
by
All About MS
on Thu 13 Dec 2007 09:23 AM CST
Using interferon beta-1b (Betaseron) therapy in patients with the first clinical symptoms of MS (MS) significantly postpones the development of more »
by
All About MS
on Thu 13 Dec 2007 04:09 AM CST
Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression WAYNE, N.J., Wednesday, November 28
by
All About MS
on Wed 28 Nov 2007 12:00 AM CST
New natural history of interferon-beta-treated relapsing multiple sclerosis. Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy. To investigate the impact ... more » |
||||||||||||||||||||||||||||||||||||||||||||||||